Key facts
- This page summarizes Adam Crystal's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Feb 2023, 15:11.
Adam Crystal - 30 Jan 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- CCCC
- Reported as of
- 30 Jan 2023
- Net transaction value
- -$10,122
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2023, 15:11:13 UTC
- Prior SEC filing
- 14 Jun 2022
- Next SEC filing
- 02 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jolie M. Siegel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adam Crystal filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 01 Feb 2023.
Change
- Previous filing in this sequence was filed on 14 Jun 2022.
- Current net transaction value: -$10,122.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCCC
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,750
- Change %
- +21%
- Price
- Shares after
- 21,398
- Date
- 30 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
CCCC
transaction
Common Stock
Tax liability
- Transaction value
- $10,122
- Shares
- -1,301
- Change %
- -6.1%
- Price
- $7.78
- Shares after
- 20,097
- Date
- 30 Jan 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CCCC
transaction
Derivative
Performance Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,750
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 18,750
- Date
- 30 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
Footnote F2
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.